SCHEMBL30544993

SCHEMBL30544993

Cc1ccc(C(=O)O)cn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.62
HDAC6 Q9UBN7 1/20 0.62
P4HA1 P13674 2/20 0.61
P4HTM Q9NXG6 2/20 0.61
MIF P14174 1/20 0.59
GABRP O00591 1/20 0.57
GABRD O14764 1/20 0.57
GABRA1 P14867 1/20 0.57
GABRB1 P18505 1/20 0.57
GABRG2 P18507 1/20 0.57
GABRB3 P28472 1/20 0.57
GABRA5 P31644 1/20 0.57
GABRA3 P34903 1/20 0.57
GABRA2 P47869 1/20 0.57
GABRB2 P47870 1/20 0.57
GABRA4 P48169 1/20 0.57
GABRE P78334 1/20 0.57
GABRA6 Q16445 1/20 0.57
GABRG1 Q8N1C3 1/20 0.57
GABRG3 Q99928 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181465 1.00 HDAC1 (0.62) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL9504571 0.98 HDAC1 (0.60) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL27889590 0.98 HDAC1 (0.60) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL7741541 0.98 HDAC1 (0.60) HDAC1HDAC6P4HA1P4HTMMIF
Benzoic Acid SCHEMBL28287250 0.92 HDAC1 (0.55) HDAC1HDAC6P4HA1P4HTMMIF
Propanol SCHEMBL28719045 0.89 MAPT (0.53) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL7528433 0.86 KDM4E (0.58) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL13320208 0.85 P4HA1 (0.55) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL30425369 0.85 P4HA1 (0.55) HDAC1HDAC6P4HA1P4HTMMIF
SCHEMBL4400941 0.84 HDAC1 (0.64) HDAC1HDAC6ALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023195790-A1 METHOD FOR MANUFACTURING BIOMATERIAL FOR TISSUE REPAIR WITH EXCELLENT SAFETY ㈜아크로스 2023-10-12 WO claimed
WO-2025034613-A1 3H-IMIDAZO[4,5-B]PYRIDINE COMPOUNDS AS NON-COVALENT MODIFIERS OF AKT1 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-02-13 WO disclosed
EP-4504719-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2025-02-12 EP disclosed
US-20240279215-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED 2024-08-22 US disclosed
WO-2023196283-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2023-10-12 WO disclosed
EP-4230623-A2 PYRIDINE COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS Revolution Medicines, Inc. (US) 2023-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240279215-A1 NAMPT MODULATORS NAMPT, SIRT1, NNT HDAC1 32/4885HDAC6 46/4885P4HA1 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.